Meningitis sequelae in Adulthood: Towards and Understanding of Residual Effects after childhood bacterial infection

Meningitis sequelae in Adulthood: Towards and Understanding of Residual Effects after childhood bacterial infection - MATURE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56904

Enrollment

184

Registered

2024-07-24

Start date

2024-09-13

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infection of the meninges Meningitis

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Childhood bacterial meningitis survivors: 1. History of childhood bacterial meningitis; 2. 18 years of age or older; 3. Fluent Dutch speaker. Control group: 1. 21 years of age or older; 2. Fluent Dutch speaker; 3. No documented diagnosis of a neurological disorder (among which meningitis).

Exclusion criteria

Exclusion criteria: 1. Absence or withdrawal of written informed consent; 2. *Complex onset* of meningitis, defined as: meningitis secondary to immunodeficiency states, central nervous system surgery, cranial trauma or cerebrospinal fluid shunt infections or relapsing meningitis; 3. Somatic disorders unrelated to meningitis, congenital disorders, and severe motor or sensory disabilities that interfere with outcome assessment at time of assessment; 4. Inability to comprehend testing instructions at time of assessment.

Design outcomes

Primary

Measure	Time frame
Main study parameters will be 1) neurocognitive outcome as measured by the Emma Toolbox (an in-depth measure of neurocognitive functioning that was developed in-house) and a short form of the Wechsler Adult Intelligence Scale IV (WAIS-IV) estimating Full Scale IQ, 2) behavioral and emotional functioning as measured by the Adult Self Report (ASR) and Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5), 3) Health related quality of life as measured by the Patient Reported Outcomes Measurement Information System (PROMIS) 29+2 Profile and the EuroQoL EQ-5D-5L, 4) Participation in society as measured by the PROMIS Ability to Participate in Social Roles and Activities (PROMIS APS) short form 8a and a custom participation questionnaire, and 5) hearing as measured by the Amsterdam Inventory for Auditory Disability and Handicap (AIADH).	—

Measure

Time frame

Main study parameters will be 1) neurocognitive outcome as measured by the Emma Toolbox (an in-depth measure of neurocognitive functioning that was developed in-house) and a short form of the Wechsler Adult Intelligence Scale IV (WAIS-IV) estimating Full Scale IQ, 2) behavioral and emotional functioning as measured by the Adult Self Report (ASR) and Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5), 3) Health related quality of life as measured by the Patient Reported Outcomes Measurement Information System (PROMIS) 29+2 Profile and the EuroQoL EQ-5D-5L, 4) Participation in society as measured by the PROMIS Ability to Participate in Social Roles and Activities (PROMIS APS) short form 8a and a custom participation questionnaire, and 5) hearing as measured by the Amsterdam Inventory for Auditory Disability and Handicap (AIADH).

—

Secondary

Measure	Time frame
Secondary study parameters will be brain structure and functioning (MRI scanning)	—

Countries

Netherlands

Outcome results